Maraviroc in treatment-experienced patients with HIV-1 infection - Experience from routine clinical practice

European Journal of Medical Research

Volumn 15, Issue 6, 2010, Pages 231-237

  Reuter, Stefan ^a   Braken, P ^a   Jensen, B ^a   Sierra Aragon, S ^b   Oette, M ^c   Balduin, M ^b   Kaiser, R ^b   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Krankenhaus der Augustinerinnen   (Germany)

Author keywords

CCR 5; CXCR 4; Genotype; Resistance testing; Salvage

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; TIPRANAVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PHENOTYPE; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ADD ON THERAPY; AGED; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DRUG INDICATION; DRUG RESPONSE; DRUG USE; FALSE POSITIVE RESULT; HYPERTRANSAMINASEMIA; MIDDLE AGED; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TROPISM;

EID: 77954409264     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-6-231     Document Type: Article

References (24)

1. de Mendoza C, Rodriguez C, Garcia F, Eiros JM, Ruiz L, Caballero E, Aguilera A, Leiva P, Colomina J, Gutierrez F, del RJ, Aguero J, Soriano V. Prevalence of X4 tropic viruses in patients recendy infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007 Apr;59(4):698-704.
2. Braun P, Wiesmann F. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur J Med Res 2007 Oct 15;12(9):463-72. (Pubitemid 350011459)
3. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007 Dec;25(12):1407-10. (Pubitemid 350233143)
4. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der RE, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008 Oct 2;359(14):1429-41.
5. Hammer SM, Eron JJ, Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 Aug 6;300(5):555-70.
6. Dolin R. A new class of anti-HIV therapy and new challenges. N Engl J Med 2008 Oct 2;359(14):1509-11.
7. Balduin M, Sierra S, Daumer MP, Rockstroh JK, Oette M, Fatkenheuer G, Kupfer B, Beerenwinkel N, Hoffmann D, Selbig J, Pfister HJ, Kaiser R. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 2005 Dec;34(4):277-87.
8. Maggiolo F, Airoldi M, Callegaro A, Ripamonti D, Gregis G, Quinzan G, Bombana E, Ravasio V, Suter F. Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance. J Int Assoc Physicians AIDS Care (Chic Ill) 2007Jun;6(2):87-93.
9. Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses 2008 May;24(5):685-94.
10. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Beilos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der RE. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008 Oct 2;359(14):1442-55.
11. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der RE, Mayer H. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009 Jun 1;199(11):1638-47.
12. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003 Feb 14;17(3):361-70.
13. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Kadama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006 Aug 5;368(9534):466-75.
14. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Kadama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008 Jul 24;359(4):339-54.
15. Flandre P, Descamps D, Morand-Jouberd L, Charpentier C, Delaugerre C, Chaix ML, et al. Comparison of the use of last genotype versus all past genotypes to classify patients according to resistance algorithms. 2009 Nov 11; Cologne, Germany 2009 p. 33.
16. Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: integration of a new antiretroviral drug class into clinical practice. J Antimicrob Chemother 2008 Jun;61(6):1187-90. (Pubitemid 351753580)
17. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007 Feb;51(2):566-75. (Pubitemid 46185274)
18. Stucki H, Wagner S, Vidal V, Hamy F, Klimkait T. HIV tropism testing using sequence and structure information of the V3 loop. 2009 Jul 19; Cape Town, South Africa 2009.
19. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006 Jun 26;20(10):1359-67. (Pubitemid 43948242)
20. Poveda E, Seclen E, Gonzalez MM, Garcia F, Chueca N, Aguilera A, Rodriguez JJ, Gonzalez-Lahoz J, Soriano V. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009 May;63(5):1006-10.
21. Recordon -Pinson P, Descamps D, Soulié C, Lazrek M, Charpentier C, Montes B, et al. Genotypic prediction of HIV-1 tropism: correlation with the virological response to maraviroc and genetic evolution on maraviroc therapy in the genotropism study. 2009 Nov 11; Cologne, Germany 2009 p. 33.
22. Sierra S, Thielen A, Jensen B, Esser S, Fatkenheuer G, Lengauer T, et al. Tropism determination and clinical outcomeof49 patients from the AREVIR cohort under MVC treatment. 2009 Nov 11 ; Cologne, Germany 2009 p. 47.
23. Harrigan PR, MOTIVATE Tropism Study Group. "Deep" sequencing to identify treatment experienced patients who respond to maraviroc (MVC). 2009 p. Abstract PE 3.3/2.
24. Jubb R, Lewis M, Simpson P, Craig C, Haddrick M, Perros M, et al. CCR5-tropic Resistance to Maraviroc Is Uncommon even among Patients on Functional Maraviroc Monotherapy or with Ongoing Low-level Replication. 2009 Feb 16; Montréal, Canada 2009.